Celgene Pulls Back From First-Line CLL As Revlimid ORIGIN Trial Terminates
This article was originally published in The Pink Sheet Daily
Executive Summary
Imbalance of deaths for Revlimid in the ORIGIN treatment-naïve CLL study could be due to the advanced age of participants or their many comorbidities. Future of drug as monotherapy in treatment-naïve patients is now unlikely, but studies in later lines of treatment go on.
You may also be interested in...
Celgene Secures Revlimid Frontline Myeloma Approval
Labeling includes new warning for development of second primary malignancies and more language about other kinds of adverse events, but there is already widespread off-label use and analysts don’t expect the warnings to have much impact.
Celgene Goes Big And Early: Aims For Two New Blockbusters And A Robust, Transformative Pipeline
The biotech has a three-pronged strategy to double revenues by 2017: continue to expand core multiple myeloma product Revlimid, bring new blockbusters online, and develop its early stage pipeline through deals.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.